Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04354129

Observational Study of Subcutaneous Immunoglobulin (Cutaquig) in Patients With Primary and Secondary Immunodeficiency.

This study will assess the relative safety, tolerability, and participant satisfaction in participants using the rapid manual push method with Cutaquig®. The hypothesis being that treatment with Cutaquig® by rapid manual push method will improve the safety, tolerability and patient satisfaction of participants with PID or SID.

Cutaquig® by rapid push is already approved in Canada and has proven to be efficacious in preventing significant infection. However, relative safety, tolerability, and patient satisfaction have not been studied in these patients. The information gained from this study will improve the safety and tolerability knowledge database and will support the optimal use of Cutaquig® - thus benefitting both physicians and patients.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Primary Immune Deficiency Disorder Congenital, Hereditary, and Neonatal Diseases and Abnormalities Genetic Diseases, Inborn Immune System Diseases Immunologic Deficiency Syndromes Primary Immunodeficiency Diseases Secondary Immune Deficiency

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Alberta

Edmonton, Alberta, T6G 2R3, Canada

About this study

Primary and secondary immunodeficiency diseases (PID and SID, respectively) affect the development and/or function of the immune system, resulting in increased frequency of infection. Treatment of these disorders using Cutaquig® (a subcutaneous immunoglobulin infusion (SCIG)) was licensed in Canada in 2018 and has proven to be effective in preventing significant infection. Other brands of SCIG can be given by the participant using a syringe (called rapid manual push method), which shows the same efficacy as administration by a programmable pump. The rapid manual push method has the potential to improve quality of life, reduce infusion time, and reduce the cost of administration. This study will evaluate the safety, tolerability, and patient satisfaction of Cutaquig® by the rapid manual push method in participants with PID or SID. It will also compare the efficacy of Cutaquig with prior SCIG treatment, if applicable, in participants with PID or SID.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients (≥ 18 years)
  • Who have PID or SID requiring IgG replacement therapy
  • For whom the investigator decides to maintain immunoglobulin replacement therapy with subcutaneous injections of Cutaquig® 165 mg/mL at home
  • Having signed an informed consent form

Exclusion criteria

-Patients currently participating in another interventional study at the time of inclusion

Treatment and study plan

Cutaquig®

Drug

Immunoglobulin replacement therapy with subcutaneous injections of Cutaquig® 165 mg/mL at home.

Other names: Immunoglobulin (human) subcutaneous 16.5% Solution for injection (165 mg/mL)

Primary outcomes

  1. Safety of Infusion Rate

    Time frame: 6 months

    • The primary objective is to assess safety of cutaquig® in patients with PID or SID by rapid push at infusion volumes ranging from 15 mL/infusion site to a maximum of 60 mL/infusion site into a maximum of 4 infusion sites and
    • assess safety of a maximum infusion speed of 120 mL/h for all sites combined (2 mL/min)

  2. Tolerability of Infusion Rate

    Time frame: 6 months

    • The primary objective is to assess tolerability of cutaquig® in patients with PID or SID by rapid push at infusion volumes ranging from 15 mL/infusion site to a maximum of 60 mL/infusion site into a maximum of 4 infusion sites and
    • assess tolerability of a maximum infusion speed of 120 mL/h for all sites combined (2 mL/min)

Secondary outcomes

  1. Questionnaire

    Time frame: 6 months

    Key secondary objectives are to assess by a questionnaire

    • time to infuse cutaquig®
    • total volume infused per infusion site
    • total volume infused per infusion
    • frequency of infusion
    • number of injection sites
    • ease of infusion (injectability) Other secondary objectives are to
    • assess patient quality of life (QoL) and patient satisfaction by using the EQ-5D-5L (descriptive system compromises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety and depression).
    • compare the injectability of cutaquig® with prior SCIG administration if applicable

Sponsors and collaborators

Lead sponsor

University of Alberta

Other

Collaborators

  • Octapharma

Registry information

Official study title

Safety, Tolerability, and Patient Satisfaction of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment by Rapid Push in Patients With Primary or Secondary Immunodeficiency (PID or SID)

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
Apr 21, 2020
Registry last updated
May 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.